In the last trading session, 2.03 million Cogent Biosciences Inc (NASDAQ:COGT) shares changed hands as the company’s beta touched 1.77. With the company’s per share price at $7.37 changed hands at -$0.2 or -2.64% during last session, the market valuation stood at $814.11M. COGT’s last price was a discount, traded about -71.1% off its 52-week high of $12.61. The share price had its 52-week low at $4.28, which suggests the last value was 41.93% up since then. When we look at Cogent Biosciences Inc’s average trading volume, we note the 10-day average is 1.34 million shares, with the 3-month average coming to 1.48 million.
Analysts gave the Cogent Biosciences Inc (COGT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.55. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended COGT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Cogent Biosciences Inc’s EPS for the current quarter is expected to be -0.57.
Cogent Biosciences Inc (NASDAQ:COGT) trade information
Instantly COGT was in red as seen at the end of in last trading. With action -8.56%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -5.51%, with the 5-day performance at -8.56% in the red. However, in the 30-day time frame, Cogent Biosciences Inc (NASDAQ:COGT) is -20.50% down. Looking at the short shares, we see there were 7.98 million shares sold at short interest cover period of 4.48 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14.5, meaning bulls need an upside of 49.17% from its current market value. According to analyst projections, COGT’s forecast low is 14 with 15 as the target high. To hit the forecast high, the stock’s price needs a -103.53% plunge from its current level, while the stock would need to soar -89.96% for it to hit the projected low.
Cogent Biosciences Inc (COGT) estimates and forecasts
Data shows that the Cogent Biosciences Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -20.32% over the past 6 months, a 0.00% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 15.33%. The 2025 estimates are for Cogent Biosciences Inc earnings to decrease by -0.39%.
COGT Dividends
Cogent Biosciences Inc is expected to release its next quarterly earnings report in February.
COMMODORE CAPITAL LP holds the second largest percentage of outstanding shares, with 9.8126% or 9.74 million shares worth $82.09 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 3.09 shares estimated at $22.76 million under it, the former controlled 2.80% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.15% of the shares, roughly 2.37 shares worth around $17.5 million.
